Unlock instant, AI-driven research and patent intelligence for your innovation.

Medication for influenza

A technology for drugs and influenza, applied in the direction of antibodies, microorganisms, antiviral agents, etc., can solve the problem that development takes a very long time, and achieve the effect of high safety

Pending Publication Date: 2020-04-24
TOKYO METROPOLITAN INST OF MEDICAL SCI
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Among various vaccines, live vaccines are one of the most effective vaccines, and it is usually known that the development of attenuated vaccines for new viruses takes a very long time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medication for influenza
  • Medication for influenza
  • Medication for influenza

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0103] 4. Antibody Preparation

[0104] (1) Preparation of polyclonal antibodies

[0105] Immunization is carried out by administering the protein or partial peptide derived from influenza virus to non-human mammals such as rabbits, dogs, guinea pigs, mice, rats, goats, etc. by themselves or together with carriers and diluents. The amount of antigen administered per animal, the amount administered when an adjuvant is used, the type of adjuvant, the site of immunization, the interval of immunization, and the like are known.

[0106] The measurement of the antibody titer in serum is also known, and can be performed by ELISA, EIA, RIA, and the like. After confirming that the antibody titer has risen sufficiently, the whole blood is collected, and the antibody can be separated and purified by a commonly performed method. Isolation and purification can be carried out by appropriately selecting known methods such as ammonium sulfate salting-out method, ion exchange chromatography,...

Embodiment 1

[0164]

[0165] 1) Preparation of recombinant vaccinia virus derived from DIs strain into which influenza virus hemagglutinin protein gene was introduced

[0166] The artificially synthesized hemagglutinin protein (HA) gene as the H5N1 HPAIV antigen is connected downstream of the vaccinia virus promoter mH5 sequence, and inserted into the plasmid vector for homologous recombination ( figure 1 ). At this time, when inserting the H5N1 subtype HA sequence, a Hind III site was used as a restriction enzyme site. By introducing a plasmid vector for homologous recombination (cutting one site with a restriction enzyme and making it linear) into CEFs previously infected with the DIs strain, the homologous recombination in the region adjacent to the gene deletion site of the DIs strain was produced. Recombinant vaccinia virus (RVV) in which the mH5 promoter and the influenza virus HA protein gene were inserted into the vaccinia virus genome, specifically, rDIs / mCl1, rDIs / mCl2.1, r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A medication for preventing or treating influenza, said medication including an inactivated influenza virus or a recombinant vaccinia virus that includes, within the genome of the vaccinia virus DIs strain, an expression promoter and all or a portion of DNA coding for an influenza virus-derived protein.

Description

technical field [0001] The present invention relates to a preventive and therapeutic agent for the onset of influenza virus infection, which is the cause of influenza. Background technique [0002] Seasonal influenza circulates every winter, and it is reported that 10 to 20% of the population suffers from it. Its pathogen is A / H1N1, A / H3N2, or B-type influenza virus, but its antigenicity changes slightly every year, so it is necessary to manufacture a vaccine conforming to its epidemic prediction strain. On the other hand, novel influenza includes H5N1 highly pathogenic avian influenza and H7N9 avian influenza. In particular, the H5N1 highly pathogenic avian influenza virus (H5N1HPAIV) first reported infected patients in 1997, and since 2003, the number of infected patients has increased mainly in China, Southeast Asia, and the Middle and Near East. Currently, more than 800 cases of infection and more than 450 deaths, equivalent to about 50% of them, have been reported. C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/17A61K35/76A61K39/145A61K39/275A61K39/395A61K45/00A61P31/16
CPCA61K35/17A61K45/00A61P31/16C12N15/86C07K14/005C12N7/00C12N2760/16121C12N2760/16134C12N2710/24143A61K39/12C07K16/2812C07K16/1018C07K16/2815C07K2317/76A61K2039/505C07K2317/73A61K39/42C12N2760/16171A61K2300/00A61K35/76A61K39/145A61K39/285A61K39/395A61K2039/5252
Inventor 安井文彦小原道法
Owner TOKYO METROPOLITAN INST OF MEDICAL SCI